OncoTargets and Therapy (Oct 2018)
Novel EXO-T vaccine using polyclonal CD4+ T cells armed with HER2-specific exosomes for HER2-positive breast cancer
Abstract
Rong Li,1,2 Rajni Chibbar,3 Jim Xiang1,2 1Cancer Research Cluster, Saskatchewan Cancer Agency, Saskatoon, SK, Canada; 2Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada; 3Department of Pathology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada Abstract: Breast cancer is the leading cause of death in women globally. The human epidermal growth factor receptor 2 (HER2)-positive breast cancer is often associated with poor prognosis and high mortality. Even though anti-HER2 monoclonal antibodies have improved the clinical outcome, resistance to the antibody therapy becomes a major obstacle in the treatment of HER2-positive breast cancer patients. Alternative approaches are therefore needed. HER2-specific vaccines have been developed to trigger patient’s immune system against HER2-positive breast cancer. This article describes the development of novel HER2-specific exosome (EXO)-T vaccine using polyclonal CD4+ T cells armed with HER2-specific dendritic cell-released EXO and demonstrates its therapeutic effect against HER2-positive tumor in double-transgenic HER2/HLA-A2 mice with HER2-specific self-immune tolerance. Therefore, our novel HER2-specific EXO-T vaccines are likely to assist in the treatment of HER2-positive breast cancer patients. Keywords: EXO-T vaccine, polyclonal CD4+, T cell, HER2, exosome, breast cancer
